Everything on Biotech

Eli Lilly is diversifying its revenue base by acquiring Merida Biosciences to reduce reliance on weight-loss drugs. The acquisition targets autoimmune and allergy treatments, securing long-term pipeline independence.

Impact: Mitigates regulatory and market saturation risks associated with single-product dependence, stabilizing long-term earnings projections.

— from Self-Storage Resilience and M&A Trends · OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News· Sep 01, 2026